SLI
1.960,48
PKT
+9,31
PKT
+0,48
%
Werbung
Analysen zu SLI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
04.02.05 | Swiss Life Outperform | HypoVereinsbank | |
03.02.05 | Roche Buy | Sarasin Research | |
03.02.05 | Swiss Life Outperform | HypoVereinsbank | |
03.02.05 | Roche Kaufen | LB Baden-Württemberg | |
03.02.05 | Novartis Übergewichten | Reuschel & Co | |
02.02.05 | Swatch (I) Buy | Sarasin Research | |
02.02.05 | Swiss Life Overweight | JP Morgan | |
02.02.05 | Roche Halten | Helaba Trust | |
02.02.05 | Roche Buy | Sarasin Research | |
03.02.05 | Roche Buy | Sarasin Research | |
01.02.05 | Zurich Insurance Buy | Sarasin Research | |
01.02.05 | UBS Neutral | Merrill Lynch | |
01.02.05 | Novartis Kaufen | SYZ & CO | |
01.02.05 | Roche Halten | Helaba Trust | |
01.02.05 | UBS Buy | Sarasin Research | |
01.02.05 | UBS Buy | Merrill Lynch | |
01.02.05 | Logitech Kauf | SYZ & CO | |
31.01.05 | Lonza Reduce | Sarasin Research | |
31.01.05 | Novartis Outperform | Credit Suisse First Boston | |
31.01.05 | Roche Buy | Sarasin Research | |
02.02.05 | UBS Outperform | Credit Suisse First Boston | |
31.01.05 | Nestlé Neutral | Sarasin Research | |
01.02.05 | Roche Neutral | Credit Suisse First Boston | |
31.01.05 | Swatch (I) Buy | Sarasin Research | |
31.01.05 | Novartis Buy | Helvea | |
28.01.05 | Holcim Verkaufen | Helaba Trust | |
27.01.05 | Lonza Buy | Helvea | |
28.01.05 | Swatch (I) Neutral | JP Morgan | |
03.02.05 | Novartis Outperformer | Sparkasse KölnBonn | |
27.01.05 | Holcim Neutral | Helvea | |
27.01.05 | Adecco SA Accumulate | Helvea | |
27.01.05 | Holcim Halten | Helaba Trust | |
26.01.05 | Novartis Market Perform | William Blair | |
26.01.05 | UBS Buy | Sarasin Research | |
26.01.05 | Lonza Reduce | Sarasin Research | |
26.01.05 | Lindt In-Line | Goldman Sachs | |
26.01.05 | Lindt Neutral | Sarasin Research | |
25.01.05 | Lonza Overweight | JP Morgan | |
25.01.05 | UBS Buy | Helvea | |
25.01.05 | Lindt Neutral | Helvea |